Business
Samsung Biologics PolyPeptide acquisition focus: $1.8B
Samsung Biologics has agreed to acquire PolyPeptide Group AG, a Swiss contract drugmaker, in an all-cash deal valued at about 1.46 billion Swiss francs…
Samsung Biologics has agreed to acquire PolyPeptide Group AG, a Swiss contract drugmaker, in an all-cash deal valued at about 1.46 billion Swiss francs…
PolyPeptide Group AG has shortlisted private equity firms EQT AB and IDG Capital for the next round of bidding in the context of takeover…